Hybrid Florbetaben PET/MRI for Imaging of Cardiac Amyloidosis
Monocentric Observational Trial for Florbetaben PET/MRI Hybrid Imaging in Patients With Cardiac Amyloidosis
University Hospital, Essen
25 participants
Dec 9, 2019
OBSERVATIONAL
Conditions
Summary
Exploration of prognostic parameters in 18F-Florbetaben PET/MRI in patients with cardiac amyloidosis. The clinical endpoints are defined as occurence of major adverse cardiac events (MACE) in amyloidosis patients. Additionally, MACE outcome stratified by PET parameters will be evaluated and individual parameters of the imaging techniques will be compared to each other (PET, MRI or echocardiography).
Eligibility
Inclusion Criteria3
- Age > 40 years
- proven Amyloidosis (ATTR or AL)
- Women: negative pregnancy test less than weeks prior imaging.
Exclusion Criteria6
- Patients receiving amyloidosis-specific treatment prior study inclusion.
- Patients participating in other clinical trails for treatment of Amyloidosis.
- Pregnancy
- Contraindiactions for MRI (eGFR<30ml/min/1.73m2; gadolinium allergy; metallic implants or device not suited for 3T MRI).
- inability of consent
- Refusal of consent
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07154381